Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Antimyeloma efficacy of thalidomide in the SCID-hu model.

Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J.

Blood. 2002 Dec 1;100(12):4162-8. Epub 2002 Aug 8.

2.

Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice.

Fujii T, Tachibana M, Dhar DK, Ueda S, Kinugasa S, Yoshimura H, Kohno H, Nagasue N.

Anticancer Res. 2003 May-Jun;23(3B):2405-11.

PMID:
12894521
3.

The development of a model for the homing of multiple myeloma cells to human bone marrow.

Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC.

Blood. 1997 Jul 15;90(2):754-65.

4.

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S.

J Natl Cancer Inst. 2003 Mar 19;95(6):437-48.

5.
6.
7.

Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.

Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T.

Pathol Int. 2004 May;54(5):285-94.

PMID:
15086832
9.

Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.

Dmoszyńska A, Bojarska-Junak A, Domański D, Roliński J, Hus M, Soroka-Wojtaszko M.

Leuk Lymphoma. 2002 Feb;43(2):401-6.

PMID:
11999576
10.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.

Br J Haematol. 2002 Feb;116(2):278-90.

PMID:
11841428
11.

[Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].

Li J, Luo SK, Hong WD, Zhou ZH, Zou WY.

Ai Zheng. 2003 Apr;22(4):346-9. Chinese.

PMID:
12703985
12.

Novel biologically based therapies for myeloma.

Anderson KC.

Cancer J. 2001 Jul-Aug;7 Suppl 1:S19-23. Review.

PMID:
11504280
13.

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.

Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G.

Ann Oncol. 2001 Jul;12(7):987-90. Erratum in: Ann Oncol 2001 Sep;12(9):1333. Cineri S [corrected to Cinieri S].

14.

Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.

Kotoh T, Dhar DK, Masunaga R, Tabara H, Tachibana M, Kubota H, Kohno H, Nagasue N.

Surgery. 1999 May;125(5):536-44.

PMID:
10330943
15.

The SCID-hu myeloma model.

Epstein J, Yaccoby S.

Methods Mol Med. 2005;113:183-90.

PMID:
15968103
17.

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ.

Anticancer Res. 2003 May-Jun;23(3B):2481-7.

PMID:
12894531
18.

[Thalidomide inhibits the angiogenic activity of culture supernatants of multiple myeloma cell line].

Chen W, Zhu J, Mirshahi F, Soria J, Mirshahi M, Soria C.

Zhonghua Xue Ye Xue Za Zhi. 2002 Oct;23(10):520-3. Chinese.

PMID:
12482348
19.

Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.

Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A.

Cancer Res. 2003 May 15;63(10):2447-53.

20.

Thalidomide for the treatment of multiple myeloma.

Hattori Y, Iguchi T.

Congenit Anom (Kyoto). 2004 Sep;44(3):125-36. Review.

PMID:
15327481
Items per page

Supplemental Content

Write to the Help Desk